
TMDX Stock Forecast & Price Target
TMDX Analyst Ratings
Bulls say
TransMedics Group Inc. has demonstrated strong performance in the transplants market, with significant year-over-year quarterly growth in donation after circulatory death (DCD) organs, particularly a 44% increase in DCD livers and a 15% increase in DCD hearts. The overall transplant volume trends indicate healthy growth, supported by a 9% month-over-month increase in DCD organs, which contributed to a combined 7% growth in the heart, liver, and lung market quarter-to-date. Future prospects appear promising with anticipated product launches and a potential revenue forecast for 4Q24 exceeding $120 million, suggesting a positive trajectory for the company’s financial performance.
Bears say
TransMedics Group Inc. has exhibited concerning trends in organ transplant volumes, with donor brain-dead (DBD) livers and hearts declining 6% year-over-year and 13% month-over-month, which could impact the company’s growth potential in the transplantation market. Despite a slight increase in revenue estimates for 2026 to $657 million, the group’s valuation multiples have decreased from 7.2x to 6.8x for 2025 EV/Sales, indicating a diminishing investor sentiment. Additionally, challenges such as competition from other technologies, potential reimbursement changes, and regulatory risks could adversely affect the adoption rate of TransMedics' proprietary organ care systems, contributing to an overall negative outlook for the company's stock.
This aggregate rating is based on analysts' research of Transmedics Group Inc and is not a guaranteed prediction by Public.com or investment advice.
TMDX Analyst Forecast & Price Prediction
Start investing in TMDX
Order type
Buy in
Order amount
Est. shares
0 shares